Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Neurology | Musculoskeletal

Multiple Sclerosis

Alabama

Tuscaloosa : Alabama Neurology & Sleep Medicine

Investigational Oral Medication for CIS (Pre-MS)

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Arizona

Gilbert : Clinical Research Advantage / Neurological Physicians of Arizona

Investigational Oral Medication for CIS (Pre-MS)

Phoenix : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Phoenix : Barrows Neurological Clinic

Investigational Oral Medication for CIS (Pre-MS)

Phoenix : Xenoscience

Investigational Oral Medication for CIS (Pre-MS)

Phoenix : Xenoscience Clinical Research Division

Investigational Oral Medication for RRMS

Scottsdale : Dept of Neurology, Mayo Clinic

Investigational Oral Medication for CIS (Pre-MS)

Tucson : Northwest NeuroSpecialists, PLLC

Clinical Research Study Available for People Diagnosed with Multiple Sclerosis

Tucson : Northwest NeuroSpecialists, PLLC

Multiple Sclerosis Study

California

Auburn : Sutter Institute for Medical Research (SIMR)

Multiple Sclerosis Data Collection Study

Berkeley : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Irvine : University of California, Irvine

Investigational Oral Medication for CIS (Pre-MS)

Loma Linda : Loma Linda University Neurology Clinical Research Center

Investigational Oral Medication for RRMS

Modesto : Sutter Gould Medical Foundation

Investigational Oral Medication for RRMS

San Francisco : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Colorado

Boulder : Alpine Clinical Research Center

Add-on Therapy of an oral medication for patients with Multiple Sclerosis, currently using Avonex, Betaseron, or Rebif.

Boulder : Alpine Clinical Research Center

New medicine for patients with Multiple Sclerosis experiencing Neuropathic Pain

Boulder : Alpine Clinical Research Center

New Oral medication for reducing the rate of clinical relapses in patients with Relapsing Remitting Multiple Sclerosis (MS)

Centennial : 1st International Clinical Research Center

Do you have Relapsing Remitting Multiple Sclerosis?

Connecticut

Fairfield : Associated Neurologists of Southern CT

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Florida

Bradenton : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bradenton : Bradenton Research

Bradenton Neurology, Inc. is participating in a nationwide research study for individuals who have been diagnosed with Multiple Sclerosis.

Maitland : Neurology Associates, P.A.

Investigational Oral Medication for CIS (Pre-MS)

Maitland : Neurology Associates

Investigational Oral Medication for RRMS

Sarasota : Negroski, Stein, Sutherland & Hanes Neurology.

Investigational Oral Medication for RRMS

St Petersburg : Suncoast Neruoscience Associates Inc.

Investigational Oral Medication for CIS (Pre-MS)

Sunrise : Neurology Clinical Research Inc.

Investigational Oral Medication for RRMS

Tampa : Meridien Research

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Vero Beach : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Georgia

Atlanta : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Atlanta : Neurotrials Research, Inc.

Have you experienced symptoms that suggest multiple sclerosis?

Atlanta : NeuroTrials Research, Inc.

Investigational Oral Medication for CIS (Pre-MS)

Suwanee : Georgia Neurology & Sleep Medicine

Investigational Oral Medication for CIS (Pre-MS)

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Illinois

Chicago : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Chicago : Northwestern University, Deptartment of Neurology

Investigational Oral Medication for CIS (Pre-MS)

Elk Grove Village : Suburban Neurologists, SC

Investigational Oral Medication for RRMS

Flossmoor : South Suburban Neurology

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Indiana

Fort Wayne : Fort Wayne Neurological Center

Investigational Oral Medication for CIS (Pre-MS)

Fort Wayne : Fort Wayne Neurological Center

Investigational Oral Medication for RRMS

Indianapolis : Josephson Wallack Munshower Neurology, PC

Investigational Oral Medication for CIS (Pre-MS)

Indianapolis : JWM Neurology PC

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Iowa

Des Moines : Ruan Neurology & Research Center

Investigational Oral Medication for RRMS

Kansas

Kansas City : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lenexa : MidAmerica Neuroscience Institute

Investigational Oral Medication for CIS (Pre-MS)

Lenexa : MidAmerica Neuroscience Institute

Relapsing forms of Multiple Sclerosis study to evaluate the safety and tolerability of two doses of an oral study drug over 24 weeks (study 7)

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Kentucky

Lexington : Associates in Neurology, P.S.C.

A Phase 2 study of LY2127399, an AntiBaff Human Antibody vs placebo for subjects with Relapsing Remitting Multiple Sclerosis

Lexington : Associates in Neurology, P.S.C.

A Phase 3 study of PEGylated Interferon Beta-1a vs Placebo for subjects with Relapsing Remitting Multiple Sclerosis.

Lexington : Baptist Neurology Center

Investigational Oral Medication for CIS (Pre-MS)

Lexington : University of Kentucky

Investigational Oral Medication for CIS (Pre-MS)

Louisiana

Shreveport : LSUHSC Dept of Neurology

Investigational Oral Medication for CIS (Pre-MS)

Maryland

Baltimore : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Massachusetts

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Michigan

Clinton Twp. : Michigan Neurology Associates, P.C.

Investigational Oral Medication for RRMS

Farmington Hills : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Grand Rapids : Michigan Medical P.C. Neurology

Investigational Oral Medication for CIS (Pre-MS)

Grand Rapids : St Mary's Healthcare

Investigational Oral Medication for CIS (Pre-MS)

Grand Rapids : St. Mary's Healthcare

Investigational Oral Medication for RRMS

Traverse City : Northern Michigan Neurology

Investigational Oral Medication for CIS (Pre-MS)

Traverse City : Northern Michigan Neurology

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Minnesota

Minneapolis : University of Minnesota Dept. of Neurology

Investigational Oral Medication for RRMS

Mississippi

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Missouri

St. Louis : Saint Louis University, Dept of Neurology

Investigational Oral Medication for CIS (Pre-MS)

Montana

Billings : Billings Clinic Research Center

Are you between the age of 18 and 65 with a diagnosis of Multiple Sclerosis?

New Hampshire

Lebanon : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

New Jersey

Lawrenceville : AdvanceMed Research

The Dignity studies are phase III international multicenter, double-blind, randomized, placebo-controlled trials of botulinum toxin (BOTOX) in patients with spinal cord injury (SCI) or multiple sclerosis (MS); BOTOX is not yet licensed for these indications.

New Mexico

Albuquerque : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Albuquerque : MS Specialty Clinic UNM

Investigational Oral Medication for CIS (Pre-MS)

New York

Albany : Upstate Clinical Research, LLC

Investigational Oral Medication for CIS (Pre-MS)

Latham : Multiple Sclerosis Center of NE New York Empire Neurology, P.C.

Investigational Oral Medication for RRMS

Mineola : Winthrop University Hospital Clinical Trials Center

Relapsing remitting multiple sclerosis

Mineola : Winthrop University Hospital Clinical Trials Center

Volunteers needed for a multiple sclerosis research study

New York : Mount Sinai Medical Center

A 21 WEEK STUDY TO EVALUATE SAFETY AND EFFICACY OF ORAL FAMPRIDINE-SR IN SUBJECTS WITH MULTIPLE SCLEROSIS.

New York : Mount Sinai Medical Center

A 24-month, double-blind, randomized, multi-center, placebo-controlled, parallel-group study comparing the efficacy and safety of FTY720 1.25mg and 0.5mg administered once daily versus placebo in patients with relapsing remitting multiple sclerosis

New York : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

New York : Mount Sinai Medical Center

A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon beta 1-a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing-Remitting Multiple Sclerosis (CombiRx Phase III)

New York : Mount Sinai Medical Center

A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Rituximab in Adults with Primary Progressive Multiple Sclerosis PROTOCOL: U2786g

New York : Mount Sinai School of Medicine; Corinne Goldsmith Dickinson Center for MS

Investigational Oral Medication for CIS (Pre-MS)

New York : Mount Sinai Medical Center

ITN020AI: A Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patient with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (MS) (STAYCIS)

New York : Mount Sinai Medical Center

OMEGA-Oral Megadose Corticosteroid Therapy of Acute Exacerbations in Multiple Sclerosis

New York : Mount Sinai Medical Center

The Establishment of a Patient Registry and Initiation of Related Projects of the New York State Multiple Sclerois Consortium

Plainview : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Schenectady : Schenectady Neurological Consultants, PC

The TYSABRI Global Observational Program in Safety (TYGRIS) is a safety observational cohort study designed to obtain long-term safety data in multiple sclerosis (MS) patients treated with TYSABRI in a clinical practice setting.

Stony Brook : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Stony Brook : SUNY Stony Brook Dept of Neurology

Investigational Oral Medication for CIS (Pre-MS)

Syracuse : Institute of Human Performance SUNY Upstate New York University

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

North Carolina

Charlotte : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Charlotte : The Neurological Institute, P.A.

Investigational Oral Medication for CIS (Pre-MS)

Charlotte : The Neurological Institute

Investigational Oral Medication for RRMS

Salisbury : Central Carolina Neurology & Sleep, PA

Looking for MS Patients for a Quality of Life Study

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Winston-Salem : Wake Forest University Health Sciences

Investigational Oral Medication for CIS (Pre-MS)

North Dakota

Bismarck : DakotaNeurology Legacy Pharma Research

Investigational Oral Medication for RRMS

Ohio

Cincinnati : Riverhills Healthcare Inc.

Investigational Oral Medication for RRMS

Cleveland : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Columbus : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Dayton : Neurology Specialists LLC

Investigational Oral Medication for CIS (Pre-MS)

Dayton : Neurology Specialists LLC

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Oklahoma

Tulsa : Neurological Associates of Tulsa

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Oregon

Portland : Providence MS Center

Investigational Oral Medication for RRMS

Tualatin : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Pennsylvania

Allentown : St. Luke's Center for Neuroscience MS Center

Investigational Oral Medication for RRMS

Philadelphia : Albert Einstein Medical Center, Neurosensory Sciences

Investigational Oral Medication for CIS (Pre-MS)

Philadelphia : Drexel University College of Medicine, Department of Neurology

Investigational Oral Medication for CIS (Pre-MS)

Philadelphia : The Comprehensive MS Center at Thomas Jefferson University

Investigational Oral Medication for CIS (Pre-MS)

Philadelphia : Drexel University College of Medicine Department of Neurology

Investigational Oral Medication for RRMS

Philadelphia : Jefferson Neurology Associates

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

South Carolina

Greenville : Alliance for NeuroResearch, LLC Absher Neurology, P.A.

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Tennessee

Cordova : Neurology Clinic P.C.

Investigational Oral Medication for RRMS

Nashville : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nashville : Vanderbilt Multiple Sclerosis Center

Investigational Oral Medication for RRMS

Various Cities : Research Center New!

FREEDOMS II - Multiple Sclerosis Study

Texas

Houston : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Houston : Kelsey Research Foundation

Investigational Oral Medication for CIS (Pre-MS)

Round Rock : MS Clinic of Central Texas

Investigational Oral Medication for CIS (Pre-MS)

San Antonio : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

San Antonio : Integra Clinical Research, LLC

Investigational Oral Medication for RRMS

Vermont

Burlington : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Burlington : Fletcher Allen Health Care, Dept of Neurology

Investigational Oral Medication for CIS (Pre-MS)

Virginia

Charlottesville : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Washington

Seattle : University of Washington

Investigational Oral Medication for CIS (Pre-MS)

Washington, DC

Washington : George Washington University, Dept of Neurology

Investigational Oral Medication for CIS (Pre-MS)

West Virginia

Charleston : Capitol Neurology

Investigational Oral Medication for RRMS

Wisconsin

Milwaukee : Regional MS Center at St. Lukes Medical Center

Investigational Oral Medication for CIS (Pre-MS)

Belgium

Edegem : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sijsele-Damme : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bulgaria

Sofia : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Canada

Montreal, QC : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Toronto, ON : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Vancouver, BC : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Czech Republic

Ostrava : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Pardubice : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Prague : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Praha : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Teplice : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Denmark

Arhus : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Finland

Helsinki : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Turku : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

France

Bordeaux : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Caen : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Clermont-Ferrand : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lyon : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Montpellier : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nimes : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Germany

Berlin : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Hamburg : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Marburg : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Tübingen : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ulm : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Italy

Milano : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Roma : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Mexico

Aguascalientes : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Chihuahua : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Netherlands

Breda : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Poland

Gdansk : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lodz : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Lublin : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Warszawa : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Romania

Bucuresti : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Targu Mures : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Russian Federation

Ekaterinburg : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kazan : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Moscow : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nizhny Novgorod : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Tyumen : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Serbia and Montenegro

Belgrade : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nis : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nova Sad : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Slovakia

Banska Bystrica : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Bratislava : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kosice : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nitra : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Spisska Nova Ves : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Spain

Barcelona : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Madrid : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Malaga : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sevilla : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Valencia : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Switzerland

Basel : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Ukraine

Kharkov : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Kiev : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Propetrovsk : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Vinnytsya : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

United Kingdom

Liverpool : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Newcastle upon Tyne : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Nottingham : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.

Sheffield : Research Site:

A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.